Formulations for PK/Efficacy/Tox Studies

Enabling Confident Preclinical In Vivo Studies with Purpose-Built Formulations

The quality of preclinical PK, efficacy, and toxicology data is fundamentally dependent on the formulation used. A poorly designed dosing formulation — one that is physically unstable, improperly solubilized, or mismatched to the dose level — introduces variability that can obscure true compound performance and lead to flawed development decisions. Crystal Pharmatech's SMART Biopharmaceutical Solutions eliminate this risk through a systematic, data-driven approach to preclinical formulation design.

Preclinical Formulation — PK/Efficacy/Tox Studies

Formulation Approaches

Preclinical Formulation Approaches

Formulation strategy is selected based on the API's physicochemical properties (solubility, pKa, LogD, BCS class), the dose level required, and the target species and route of administration. Crystal Pharmatech applies a structured decision framework to select the most appropriate approach:

Conventional Formulations (Solution or Suspension-Based)

Used where intrinsic solubility permits adequate drug exposure. Key strategies include:

pH adjustment
Co-solvent systems
Surfactant-based solubilization
Cyclodextrin complexation
In-situ salt formation

Enabling Formulations (For Solubility-Limited Compounds)

Where conventional approaches cannot achieve the required exposure, enabling formulation technologies are deployed:

Amorphous Solid Dispersion (ASD)
Nanosuspension by wet milling (particle size < 1,000 nm)
Micronization by jet milling (particle size 1–10 μm)
Lipid-based formulations (LBF)

Rapid ASD Screening for Early-Stage Programs

Of the enabling formulation technologies listed above, ASD is the most technically involved and the one where early-stage programs most often lose time. ASD requires systematic polymer selection, spray-drying optimization, amorphous state confirmation, and in vitro dissolution screening before a reliable prototype is ready for in vivo use.

Crystal Pharmatech has built a purpose-designed Rapid ASD Screening workflow specifically to compress this timeline. For programs where ASD has been identified as the appropriate enabling strategy, we deliver PK/Tox-ready prototype formulations in 2–4 weeks — without shortcutting the scientific steps that determine whether the ASD will actually perform in vivo:

Step 01

API Thermal Characterization and Miscibility Screening

Step 02

Polymer and Surfactant Selection

Step 03

Prototype ASD Generation

Step 04

In Vitro Performance Screening and Lead Selection

Achieve Your Success with Our Expertise

Have a question or need support with your project? Please complete the form, and our team will get back to you shortly.  

Our capabilities span three specialized platforms:

Small Molecule
Crystal Bio Solutions
Crystal NAX

By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your inquiry. The information you submit will be governed by our Privacy Policy.